OHCA 2014-43

August 15, 2014

Re: Long Acting Reversible Contraceptive Devices

Dear Provider:

Long Acting Reversible Contraceptive (LARC) devices are proven to be effective in the reduction of unintended pregnancies and their potential negative health outcomes for both infant and mother. Effective September 12, 2014, the Oklahoma Health Care Authority (OHCA) will allow separate reimbursement for LARC devices outside the Diagnosis Related Group (DRG) payment methodology when placed immediately postpartum (while the member is still inpatient).

Separate reimbursement will be allowed for the following LARC devices:

- J7300 – Intrauterine copper contraceptive
- J7301 – Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5mg
- J7302 – Levonorgestrel-releasing intrauterine contraceptive system, 52mg
- J7307 – Etonogestrel (contraceptive) implant system

In order for a facility to receive reimbursement for the LARC device, a separate outpatient claim must be filed from the inpatient facility claim, utilizing the codes noted above.

Physicians may receive reimbursement for placement utilizing the appropriate procedure code and place of service on a HCFA-1500. Members of the American College of Obstetrics-Gynecology may access the practice bulletin on LARC devices at the following link:

- [http://journals.lww.com/greenjournal/Citation/2011/07000/Practice_Bulletin_No_121_Long_Acting_Reversible.31.aspx](http://journals.lww.com/greenjournal/Citation/2011/07000/Practice_Bulletin_No_121_Long_Acting_Reversible.31.aspx)

For questions or additional information, please call (800) 522-0114.

Thank you for your continued service to Oklahoma’s SoonerCare members.

Sincerely,

Garth L. Splinter, MD
State Medicaid Director